On the treatment of hemorrhage in patients with hemophilia and associated inhibitors [3]

Transfusion

Volumn 41, Issue 12, 2001, Pages 1628-1629

  Tarantino, Michael ^a   Aledort, Louis ^b  

^a Comprehensive Bleeding Disorders Center Peoria ^*  (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 8 CONCENTRATE; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

BLEEDING; COST; DRUG CHOICE; HEMOPHILIA; HUMAN; LETTER;

ANIMALS; BLOOD COAGULATION FACTORS; DECISION MAKING; FACTOR VII; FACTOR VIII; HEMOPHILIA A; HEMORRHAGE; HUMANS; ISOANTIBODIES; RECOMBINANT PROTEINS; SWINE;

EID: 0035689590     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.2001.41121628.x     Document Type: Letter

References (7)

1. The use of por cine factor VIII concentrate (Hyate C) in the treatment of patients with inhibitor antibodies to factor FVIII: A multicenter US experience
2. Treatment of inhibitor patients with activated Prothrombin complex concentrates
3. The use of factor eight inhibitor by-passing activity (FEIBA Immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors
4. The treatment of acquired factor VIII inhibitors: Worldwide experience with porcine factor VIII concentrate
5. Use of prothrombin complex concentrates and activated prothrombin complex concentrates as prophylactic therapy in haemophilia patients with inhibitors
6. Recombinant factor VIIa versus aPCCs in haemophiliacs with inhibitors: Treatment and cost considerations
7. Economic aspects of haemophilia care in the United States